Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Robert L GottliebCarlos E VacaRoger ParedesJorge MeraBrandon J WebbGilberto PerezGodson OguchiPablo RyanBibi U NielsenMichael BrownAusberto HidalgoYessica SachdevaShilpi MittalOlayemi OsiyemiJacek SkarbinskiKavita JunejaRobert H HylandAnu OsinusiShuguang ChenGregory CamusMazin AbdelghanySantosh DaviesNicole Behenna-RentonFrank DuffFrancisco M MartyMorgan J KatzAdit A GindeSamuel M BrownJoshua T SchifferJoshua A Hillnull nullPublished in: The New England journal of medicine (2021)
Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. (Funded by Gilead Sciences; PINETREE ClinicalTrials.gov number, NCT04501952; EudraCT number, 2020-003510-12.).